Italy Antifungal Drugs Market Size & Outlook, 2023-2030
Italy antifungal drugs market, 2018-2030 (US$M)
Related Markets
Italy antifungal drugs market highlights
- The Italy antifungal drugs market generated a revenue of USD 312.9 million in 2023 and is expected to reach USD 405.2 million by 2030.
- The Italy market is expected to grow at a CAGR of 3.8% from 2024 to 2030.
- In terms of segment, azoles was the largest revenue generating drug class in 2023.
- Echinocandins is the most lucrative drug class segment registering the fastest growth during the forecast period.
Antifungal drugs market data book summary
| Market revenue in 2023 | USD 312.9 million |
| Market revenue in 2030 | USD 405.2 million |
| Growth rate | 3.8% (CAGR from 2023 to 2030) |
| Largest segment | Azoles |
| Fastest growing segment | Echinocandins |
| Historical data | 2018 - 2022 |
| Base year | 2023 |
| Forecast period | 2024 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Azoles, Echinocandins, Polyenes, Allylamines |
| Key market players worldwide | Novartis AG ADR, Pfizer Inc, Bayer AG, Sanofi SA, Merck KGaA, Merck & Co Inc, GlaxoSmithKline, Abbott Laboratories, Enzon Pharmaceuticals Inc, Astellas Pharma Inc, Glenmark Pharmaceuticals |
Other key industry trends
- In terms of revenue, Italy accounted for 2.0% of the global antifungal drugs market in 2023.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
- In Europe, Germany antifungal drugs market is projected to lead the regional market in terms of revenue in 2030.
- UK is the fastest growing regional market in Europe and is projected to reach USD 1,215.7 million by 2030.
Azoles was the largest segment with a revenue share of 47.84% in 2023. Horizon Databook has segmented the Italy antifungal drugs market based on azoles, echinocandins, polyenes, allylamines covering the revenue growth of each sub-segment from 2018 to 2030.
Companies such as Basilea Pharmaceutica Ltd. and Astellas Pharma Inc. play a crucial role in Italy. Recently, CRESEMBA (isavuconazole), an azole antifungal product, was launched in Italy for the treatment of invasive aspergillosis and mucormycosis.
The drug was co-developed by Basilea Pharmaceutica Ltd. and Astellas Pharma Inc. In addition, in Italy, Basilea Pharmaceutica Ltd. sponsors medical education events on developments and current challenges in the management of invasive fungal infections, helping create awareness about the treatment.
Such strategic initiatives are expected to strengthen the company’s presence in the country. The Italian Drugs and Medicines Agency (Agenzia Italiana del Farmaco or AIFA) is a government body operating on the principles of transparency, efficiency, and autonomy under the supervision of the Ministry of Health and the Ministry of Health Economy.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Antifungal Drugs Market Scope
Antifungal Drugs Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
Italy antifungal drugs market size, by drug class, 2018-2030 (US$M)
Italy Antifungal Drugs Market Outlook Share, 2023 & 2030 (US$M)
Related regional statistics
No records
No related regions found.
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
